Skip to main content

Hello, Pierce and Georgia,

I wanted to start off by saying what a wonderful job, Pierce, summarizing and expanding on this talk. I think you did an incredible job capturing the key takeaways.

I wanted to discuss the ESKAPE pathogens as well with you, as these pathogens are the leading cause of nosocomial infectious throughout the world [1]. These pathogens are known to be multidrug resistant and although antibodies are the gold-standard/ go to for treating these infectious, I wondered if we are approaching them appropriately. My personal research looks at antimicrobial peptides, using a nanoparticle release system, as we are seeing sexually transmitted infectious such as Neisseria gonorrhoea become antibiotic resistant [2]. My question coincides with Georgia, do you think we will see a comparison in our future for these alternate treatment methods? And do you think there will be a focus on alternate methods to avoid this ongoing issue, antibiotic resistant organisms?

References:
[1] Santajit, S., & Indrawattana, N. (2016). Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed research international, 2016, 2475067. https://doi.org/10.1155/2016/2475067

[2] Tshokey T, Tshering T, Pradhan AR, Adhikari D, Sharma R, Gurung K, Dorji T, Wangmo S, Dorji U, Wangdi K. Antibiotic resistance in Neisseria gonorrhoea and treatment outcomes of gonococcal urethritis suspected patients in two large hospitals in Bhutan, 2015. PLoS One. 2018 Aug 1;13(8):e0201721. doi: 10.1371/journal.pone.0201721. PMID: 30067836; PMCID: PMC6070275.

Name
Kyla

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.